Pedersen & Partners welcomes Alister Henton to their team in London

May 15, 2024 - London, United Kingdom – Pedersen & Partners, a leading global Executive Search and Leadership Consulting firm with 54 wholly owned offices in 50 countries, welcomes Alister Henton in capacity of Client Partner, focusing on the Lifesciences & Healthcare practice.

With nearly 30 years of experience in the industry, Alister has honed his expertise in identifying mid-management and C-Suite talent and fostering meaningful connections within the industry. His career in the recruitment sector dates back to 1994, encompassing various roles across different sectors and disciplines. He has been instrumental in cultivating partnerships with leading pharmaceutical, biotechnology, and medical device firms, earning a reputation for a deep understanding of the industry's unique talent needs. Most recently, Alister was a Partner with a Management Consulting firm in London, where he focused on Executive Search & Real-World Evidence promotion in the Life Sciences sector. Prior to this, he served as a Director with an Executive Search Consultancy, specializing in Healthcare, Life Sciences, and Tech sectors.

Guido Bormann

"I am delighted to welcome Alister to our team. His extensive experience and deep industry understanding make him a valuable addition as we continue to strengthen our presence in the UK market, especially in Lifesciences. His strategic planning knowledge and business management skills will undoubtedly contribute to our continued success in the region and the Lifesciences & Healthcare practice," stated Guido Bormann, Partner, and Head of Western Europe at Pedersen & Partners.

Lydia van der Meulen corporate

“We are pleased and proud that Alister is enhancing our international team of Life Sciences and Healthcare consultants with his knowledge, expertise, and international network across the industry. Expanding our team deepens our presence in this domain and thus our abilities to serve and support clients with their senior hiring needs in Pharma, Biotech, MedTech, and Diagnostics, both in the UK and across international markets,” added Lydia van der Meulen, Client Partner and Global Head of Life Sciences & Healthcare Practice Group.

Alister Henton

"Pedersen & Partners' international footprint presents a unique opportunity to collaborate with colleagues across regions, leveraging our collective expertise to serve our clients better. I am excited to work with such a talented team and help our clients find the best talent in the industry," stated Alister Henton, Client Partner at Pedersen & Partners.

 

Pedersen & Partners is a leading global Executive Search and Leadership firm. We operate 54 wholly owned offices in 50 countries across Europe, the Middle East, Africa, Asia & the Americas. Our values Trust, Relationship and Professionalism apply to our interaction with clients as well as executives.

Insights from the 2024 Life Sciences Breakfast Seminar: M&A and Funding in Life Sciences

April 12th, 2024, Amsterdam

Pedersen & Partners and CMS Amsterdam co-hosted this week’s M&A and Funding in Life Sciences Breakfast Seminar. The event provided a lively and agile atmosphere for representatives of well-known and international life sciences companies and scale-ups to discuss, debate, and network.

CMS Amsterdam Seminar Life Sciences 2024

 

The event gathered more than 60 decision-makers to ensure a range of perspectives. The panel discussions were led by: Erik van den Berg (CEO, Memo Therapeutics AG); Martijn Boot (Head of Legal, Brocacef); Dr. Jan Groen (CEO, Intravacc); Jos Lunenberg (CEO, Surfix Diagnostics); Koenraad Wiedhaup (CEO, Leyden Labs).

The panel discussion was co-chaired by Pieter van Duijvenvoorde (Partner, Corporate / M&A Practice, CMS Amsterdam); Ellen Gielen (Partner, Head of Lifesciences & Healthcare, CMS Amsterdam); and Lydia vdMeulen (Client Partner, Head of Life Sciences & Healthcare Practice Group at Pedersen & Partners).

The top takeaways from the event:

  • M&A, investment and fundraising dynamics: the market has ‘normalised’ and last year proved difficult for fundraising, although there are funding opportunities to be found in the USA and Asia. In terms of deals, there is a noticeable shift to companies that are in a later stage of development.
  • External factors: the Netherlands may lose its ability to build innovations by bringing together (international) talent, (international) scientists and capital.
  • Regulatory constraints or threats affecting M&A and investments: the upcoming EU Pharma package will result in less access to new medicines for EU member states.
  • Exit strategies & market climate: exit strategies should be clear at an early stage. The exit environment has improved and an increase in IPOs is expected in 2025-26.

Pedersen & Partners is a leading global Executive Search and Leadership Consulting firm. We operate 54 wholly-owned offices in 50 countries across Europe, the Middle East, Africa, Asia & the Americas. Our values of Trust, Relationship and Professionalism apply to our interaction with clients as well as executives.

Boston, USA

Leading Global Executive Search & Leadership Consulting firm in Boston, Massachusetts.

Being at the forefront of Technology, Life Sciences, and Private Equity the Boston office serves as the firm’s strategic hub for Executive Search & Leadership Consulting in North America and serves as the gateway to Europe.

Utilizing our global platform which combines our local knowledge and global industry expertise, Pedersen & Partners team offers unmatched insights and access to top level executive talent across various sectors.

Miami, USA

Leading Global Executive Search & Leadership Consulting firm in Miami, Florida.

With a focus on Technology, Consumer, Industrial, and Life Sciences the Miami office serves as the firm’s strategic hub for Executive Search & Leadership Consulting in North America and serves as the gateway to Latin America.

Utilizing our global platform which combines our local knowledge and global industry expertise, Pedersen & Partners team offers unmatched insights and access to top level executive talent across various sectors.

 

Legal function evolving to Strategic Business Partner

By Lydia Van Der Meulen, Global Head of the Life Sciences & Healthcare Practice Group:

Agnieszka Kosowska

This article is to share the insights from our periodical internal industry seminar, in which we had the privilege to host the Amsterdam/Warsaw based Agnieszka Kosowska, until recently General Counsel at Polpharma Biologics Group BV, an ambitious, fast-growth private European biologics business.

Agnieszka Kosowska is an attorney at law and currently the owner of CGC Law, advising businesses on complex compliance, governance, and stakeholder communication matters. She has been a member of several supervisory boards and has extensive experience with leading international firms such as Roche, Colgate Palmolive, PwC, and White & Case, implementing legal, compliance, risk and communication standards across a range of geographies.

Agnieszka shared her insights focusing on the key success factors for leaders tasked with governance in rapidly evolving businesses – from start-ups, scale-ups to high growth companies.

“Long gone are the days when the in-house lawyer handled contracts and the occasional dispute. Today, in most companies the role is that of a key business partner and member of the leadership team.” Governance is not limited to compliance and risk mitigation, but a critical foundation for commercial partnerships with large multinationals, as well as for business financing by commercial banks or investors. Failing in corporate governance and lack of internal controls can hinder business success. Professionalising the role of Legal as a Business Partner function will support sustainable growth.

From personal experience Agnieszka knows most fast-growth businesses are not bringing in a General Counsel soon enough. She shared reflections and learnings from her own career, including the recent four years of, as she stated ‘a colorful adventure’ with a company that started as a spin out in 2019 with a small team, scaled to 1200 personnel at six locations in 2023 – operating on the global market of biosimilars, nearly 700 mln EUR (3 bln PLN) in investment today. She enjoyed stepping up as experienced Corporate Lawyer to General Counsel, yet needed to hit the ground running. She was faced with an urgent need to implement number of key processes in several important areas simultaneously in a rapidly growing company. Over the course of her career, she has proven Legal’s added value (read: ROI) in negotiating complex deals with government and commercial partners, and managing material risks during fast-growth times.

The term "support functions" greatly underplays the critical role these areas have in the growth, development, and success of a company. Today, understanding the company, the market(s) and competitive landscape are as important to Counsel as is legal expertise. Risk management, regulatory and legal compliance, shareholder rights, corporate governance, and often public affairs are implemented and overseen by the legal function. This frequently includes involvement in strategy development and planning for the company, whether public or private. The scope will continue to expand with new ESG regulations and reporting requirements.

We were delighted to welcome Agnieszka to inspire our team. As an Executive Search & Leadership Consulting firm, Pedersen & Partners is committed to enhancing our knowledge of the industries with which we work, including all domains of Life Science & Healthcare.

Insights from Jonathan Chesnut PhD Senior R&D Director, Cell Biology

By Kristina Vaivadaite, Client Partner, Life Sciences Practice 

Insights from Jonathan Chesnut PhD Senior R&D Director, Cell Biology

This Market Pulse is to look back on the internal industry insights seminar, in which we had the privilege to host the California based Jonathan Chesnut PhD, Senior R&D Director Cell Biology at Thermo Fisher Scientific, a leading company in scientific research and analytical instrumentation.

Jonathan Chesnut received his PhD in Cell and Molecular Biology at the University of California. After his post-doctoral research, he joined Introgen as a research scientist. Currently, Jonathan Chesnut is leading a team in the cell biology business unit at Thermo Fisher Scientific R&D site in Carlsbad, California, focusing on cell engine therapy platform development.

At this firm-wide symposium, Dr. Chesnut delved into the intricacies of genome editing, particularly using CRISPR technology, its impact on cell therapy and its potential to revolutionize the field of human disease treatment. He highlighted the primary goal of precisely cutting DNA at specific locations and explained how genome editing is used to reprogram T-cells into potent anti-tumour agents.

Dr. Chesnut acknowledged the costly process and the ongoing efforts to reduce treatment costs. He also highlighted the potential for allogeneic therapies to expand access and significantly lower treatment costs.

Significant growth in the genome editing market is projected over the next few years, with a strong focus on cell therapy. It is expected that the gene editing market will reach around USD 10.5 billion in 5 years. North America is currently leading in this field, but growth is also expected in Europe and China.

The increasing demand for professionals in the field of cell therapy and genome editing is creating a workforce gap. Strategies are being developed to close this gap, including advanced education and professional certification programs.

Overall, Dr. Jonathan Chesnut provided the Pedersen & Partners team with insight into the evolving landscape of genome editing and cell therapy. He related this topic to the need for skilled professionals to drive this field forward. Pedersen & Partners’ mission is supporting clients in helping to find and recruit emerging leadership talents. With a track record in the growth domain of Cell & Gene, Pedersen & Partners' services can be beneficial for the industry.

Industry Pulse Global Life Sciences & Healthcare Practice – ESG in Pharma, Biotech, and Healthcare

By Lydia van der Meulen and Michael Ade, team members of the Pedersen & Partners Life Sciences & Healthcare Practice Group.

Pedersen & Partners holds regular internal symposia for its global team, featuring senior executives from the Life Sciences & Healthcare ecosystem as external guest speakers. These interactive sessions serve as a platform for industry leaders who are willing to share their insights into prevailing international market trends. By holding these periodical meetings, we aim to update the extended team of consultants across our firm on the most significant global developments within the industry domain.

Teaser Image LS Industry Pulse Dr Lioy

During the most recent Market Pulse symposium, we had the pleasure of hosting Eduardo Lioy PhD MBA. Dr. Lioy’s presentation focused on the global efforts for Sustainable Development driven by the United Nations, as well as the evolving international regulatory framework and its relevance to the pharmaceutical industry.

Eduardo Lioy is a respected authority in the field, and has played a pivotal role in formulating and implementing Environmental, Social and Governance (ESG) strategies for global organisations. Dr. Lioy has a distinguished background including a PhD in Chemistry & Biochemistry, an Executive MBA, and 20 years’ experience at Bristol-Myers Squibb and Boehringer Ingelheim. In particular, as Head of Corporate Sustainable Development at Boehringer Ingelheim Dr. Lioy established its first global Sustainable Development (ESG) Framework.

Dr. Lioy discussed the current and forthcoming regulatory changes, with a specific focus on the European Union. Notably, he highlighted the significant impact that the EU Corporate Sustainability Reporting Directive (EU CSRD) will have on shaping corporate strategies, business operations, and leadership expectations. Forward-thinking leadership will be imperative in the EU pharmaceutical sector in order to effectively implement the EU CSRD and work within this framework.

Dr. Lioy illustrated his discussion with several examples of ESG best practices in this sector, including environmental examples such as GSK's commitment to achieving net zero emissions across their full value chain by 2030 and Sanofi's innovative circular blister manufacturing and recycling concept. On the social side, Pfizer's Accord for a Healthier World initiative stands out with its ambition to provide access to its full portfolio of medicines for providing effective treatments to over a billion patients in low-income countries on a non-profit base, while Genentech's Advancing Inclusive Research Alliance aims to broaden clinical trial access for underserved populations.

Finally, Dr. Lioy highlighted the adoption of ESG Scorecards, as well as financial and non-financial incentive mechanisms by prominent pharmaceutical and biotech companies to promote ethical leadership across senior and middle management.

We were delighted to have Eduardo Lioy PhD MBA as a guest, and would like to thank him for his presentation and for sharing his insights in ESG trends in the Pharmaceutical industry.

About the Authors:

Lydia van der Meulen is a Client Partner and the Global Head of Life Sciences & Healthcare Practice Group at Pedersen & Partners, based in Amsterdam, the Netherlands.

Lydia van der Meulen

Mrs. van der Meulen has almost 25 years of global end-to-end Life Sciences Executive Search expertise. She draws on an extensive track record gained in senior-level international assignments across a broad range of leadership roles in the Pharmaceutical, Medical Technology, and Biotechnology sectors, as well as in Animal Health and AgriTech. During her career, Mrs. van der Meulen has worked for start-ups, mid-sized organisations and multinationals; publicly listed, privately held, and PE-backed firms. Prior to joining the Executive Search sector, Mrs. van der Meulen worked in Management Consulting in London and in Private Banking in the Netherlands. Between 1989-1990 Ms. Van der Meulen lived and worked in Kuwait. 

Michael Ade is a Client Partner at Pedersen & Partners and a dedicated member of the international Life Sciences and Healthcare Practice Group.

Michael Ade

Following a 14-year international career in the Life Sciences industry, Mr. Ade has been working in Executive Search for almost 15 years, with his expertise in conducting searches for C-Suite level executive and senior management roles in R&D, commercial, and General Management functions for companies in the Biotech, MedTech, and Pharmaceutical industry. He has a strong track record of successful placements across Europe. Prior to joining Pedersen & Partners, Mr. Ade was a Senior Partner with two international search firms, specialising in Life Sciences. He previously worked in senior and international positions in Business Development and Marketing at Ingenium Pharmaceuticals GmbH and Boehringer Ingelheim.

September – 2023

Industry Pulse Global Life Sciences & Healthcare Practice – Gene Therapy: Pricing and Reimbursement Challenges

By Lydia van der Meulen, Client Partner, Global Head of Life Sciences & Healthcare Practice Group, and Michael Ade, Client Partner, Pedersen & Partners.

Pedersen & Partners conducts regular interactive sessions for its global team, bringing in senior executives from the Life Sciences & Healthcare ecosystem to update the team on developments that impact the global Industry. In our ongoing Market Pulse symposium series, we invite industry leaders to share insights on current market trends.

During the most recent Market Pulse symposium, we had the privilege of hearing from Dr. Hardo Fischer. He shared insights into the current challenges facing Pricing & Reimbursement for Advanced Therapy Medicinal Products (ATMPs), particularly in gene therapy. We were delighted to welcome Dr. Hardo Fischer to our Market Pulse symposium. We are committed to enhancing our knowledge of the industries with which we work, positioning us optimally to serve our global clients in 50 countries, spanning all domains of Life Science innovation.

Website banner for Article LS Michael Ade

Dr. Hardo Fischer is a distinguished authority in the field, having successfully navigated gene therapy products through Regulatory and Health Technology Assessment (HTA) processes in various European countries. With experience at AveXis / Novartis Gene Therapies, he now serves as the Medical Director at GenSight Biologics.

During the symposium, Dr Fischer delved into the diverse regulatory pathways for innovative treatments in the USA, the European Union, and Switzerland, providing valuable insights to the Pedersen & Partners team. He emphasised the significant disparities in definitions of ATMPs, regulatory routes, and timelines across these regions.

Furthermore, he highlighted the promising potential of Digital Endpoints in clinical trials for ATMPs, which can overcome the limitations associated with conventional endpoints such as the Six Minute Walk Test.

Finally, Dr Fischer showcased compelling instances of applying real-world evidence to assess ATMPs, foreseeing the increased use of RWE by global authorities in future Health Technology Assessments and Pricing & Reimbursement negotiations, with the USA leading the way, as is often observed in our industry.

About the Authors:

Lydia van der Meulen is a Client Partner and the Global Head of Life Sciences & Healthcare Practice Group at Pedersen & Partners, based in Amsterdam, the Netherlands.

Lydia van der Meulen

Mrs. van der Meulen has almost 25 years of global end-to-end Life Sciences Executive Search expertise. She draws on an extensive track record gained in senior-level international assignments across a broad range of leadership roles in the Pharmaceutical, Medical Technology, and Biotechnology sectors, as well as in Animal Health and AgriTech. During her career, Mrs. van der Meulen has worked for start-ups, mid-sized organisations and multinationals; publicly listed, privately held, and PE-backed firms. Prior to joining the Executive Search sector, Mrs. van der Meulen worked in Management Consulting in London and in Private Banking in the Netherlands. Between 1989-1990 Ms. Van der Meulen lived and worked in Kuwait. 

Michael Ade is a Client Partner at Pedersen & Partners and a dedicated member of the international Life Sciences and Healthcare Practice Group.

Michael Ade

Following a 14-year international career in the Life Sciences industry, Mr. Ade has been working in Executive Search for almost 15 years, with his expertise in conducting searches for C-Suite level executive and senior management roles in R&D, commercial, and General Management functions for companies in the Biotech, MedTech, and Pharmaceutical industry. He has a strong track record of successful placements across Europe. Prior to joining Pedersen & Partners, Mr. Ade was a Senior Partner with two international search firms, specialising in Life Sciences. He previously worked in senior and international positions in Business Development and Marketing at Ingenium Pharmaceuticals GmbH and Boehringer Ingelheim.

AI or Executive Search? pharmaINSIDE interview with Christine Konlechner-Leeb, Client Partner

 
How did you get into the healthcare industry? Who were your influences?

After graduating from the University of Economics and Business, I first started my career as a brand manager for the SWATCH Group, moving laterally to the pharmaceutical industry a few years later. At that time, my entry into the industry was supported by Mr. Helmut Hasibeder, then Managing Director of Takeda Austria, as well as Roman Gamerith and Clemens Schödl. I am still in friendly contact with these mentors to this day!

pharmaINSIDE Interview with Christine Konlechner-Leeb, Client Partner at Pedersen & Partners

What was your motivation for switching to Executive Search?

I have worked for twenty years with some of the biggest names in this field, including Abbott, Sanofi, Philips and Thermofisher Scientific on an international level, taking care of the commercial business. These companies want the best teams, and they will stop at nothing to find employees who are the best fit for them.

Personnel are at the heart of each company – a business is only as successful as the people who run it. At some point I decided that I wanted to focus more on people than products, which is why these days I bring people and companies together by building bridges for them. This gives me the opportunity to communicate with the smartest, most successful, and most interesting people in the field, and to gain insights into new technologies and learn something new every day.

The market is very dynamic, and we are witnessing many new developments, especially in Artificial Intelligence, Deep Learning, Robotics Surgery, Nanotechnology, Radiomics, Genetics and Telemedicine. It’s never boring.

How do you see the industry in general and the current developments now? Prosperous? Dragging? And why is that?

Recruiting companies that have been active in Austria for many years, especially in the classic pharmaceutical sector, now often have problems finding candidates who are willing to change, and off-limits companies are also becoming a hurdle in this respect.

Increasingly, Austrian companies are also commissioning service providers who truly work internationally, meaning that they can offer a more comprehensive view of the candidate market.

The life science industry in Austria is a small market; many positions, especially in the scientific field, but also in the commercial field, can no longer be covered with Austrian candidates alone if you want the best of the best. This means that a somewhat broader perspective is needed.

Very often we hear from market participants that it is becoming increasingly difficult to fill vacancies due to a lack of suitable candidates, but we don’t have that problem – if anything, quite the opposite! Through our international network, we have contact with talented people who are willing to change and relocate. Austria is an interesting location.

How do you see the change in the industry in terms of personnel?

Executive Search has changed a lot. What we are seeing here is a dynamic development: a transformative process, moving away from the traditional personnel consulting with a psychology angle, towards using industry experts as sparring partners for staffing decisions.

The search for talent has evolved; it’s about understanding what our clients are doing, getting to grips with their technologies and gaining a deeper understanding to be able to carry out competence checks. Of course, this is about professional competence, but it is even more about personal competence. The notion of the traditional “position” into which people are to be fitted is an outdated model, because now we think about the role itself, the tasks it covers, and the individual competencies that are needed to be able to successfully fulfil them.

Do you have a special focus in your client portfolio?

At Pedersen & Partners, global industry-dedicated practice groups work in synergy with on-the-ground teams in the geographies in which we operate. Client Partners who are focused on topics such as life science, finance or real estate meet regularly to exchange information on the latest developments in the markets. In this way, we ensure that we can offer our clients appropriate insights and market know-how.

Personally, I enjoy working with start-ups, scale-ups, and medium-sized companies. The dialogue and exchange with the respective teams is exciting, direct, and personal – after all, it’s all about people.

At Pedersen & Partners, we generally strive to develop sustainable long-term relations with our clients based on our three pillars: trust, relationship, and professionalism.

Your company is multinational. What advantage does this have for your clients in the dense market of executive search?

At Pedersen & Partners, we work globally as one team and can therefore recruit for the international branches of our Austrian clients abroad and vice versa. Our clients have a local contact person, and we take care to bring in the required market expertise regardless of geography – the “Best Team Forward!”

We are an executive search and board-level search firm, but of course, we do not only search for C-level positions. We get mandates to fill key positions that are of importance for the future development of the company, roles with a complex profile or for a niche area of the business. Suitable candidates for such roles cannot simply be found with an ordinary job advertisement – it takes much more know-how, project focus and active networks in the respective area to be able to attract the right kind of talent.

What qualities or preparations do you expect from an applicant? How deep does the preparation have to be?

We do not expect this kind of preparation from our candidates – often, they do not even know which company we are talking about in the first place. Our conversations with professionals are not conducted like classic interviews, but more like eye-level conversations. It is important for us to understand the candidates’ ideas and ambitions, as well as those of our clients. We build bridges, and these bridges must be firmly anchored at both sides to be sustainable. It’s not about just mediating someone.

Does individuality in the person’s profile count as much as an “impeccable CV”?

I would like to turn this question back on you and ask “what, to you, is an impeccable CV?” The classic CV, unfortunately still requested by many HR managers, is a rather outdated model.

We are always more interested in the person who stands behind the CV, than whether they hitchhiked through South America for eight months, or took care of their elderly parents for a year. Interruptions are normal; they may have no bearing whatsoever on a person’s qualifications, or they may say a lot about that person.

How do you think the industry will develop? Will the doom-mongering about AI be confirmed?

In many areas, AI and other technical tools provide excellent support for talent acquisition activities, especially in large companies. High volumes of applications for job advertisements and through career portals can thus be successfully managed.

However, I don‘t think that AI will make our particular recruiting techniques obsolete any time soon. Executive search is not off-the-rack, but made-to-measure. We are skilled tailors, measuring each individual, ensuring the perfect fit.

Christine Konlechner-Leeb

Christine Konlechner-Leeb is a client partner with Pedersen & Partners. She focuses on leading Executive Search and leadership mandates in the sector of Life Sciences and MedTech in Europe. Ms. Konlechner-Leeb brings along more than twenty years of experience in commercial roles with international companies where she focused on business development and sales on pharmaceuticals, biotechnology, medical devices and diagnostics.

 

 

By Herbert Pachler, pharmaINSIDE

Los Angeles, USA

Leading Global Executive Search & Leadership Consulting firm in Los Angeles, California.

With a focus on Technology, Consumer, Life Sciences, and Private Equity the Los Angeles office serves as the firm’s strategic hub for the Western United States for Executive Search & Leadership Consulting and serves as our gateway to Asia Pacific.

Utilizing our global platform which combines our local knowledge and global industry expertise, Pedersen & Partners team offers unmatched insights and access to top level executive talent across various sectors.

Subscribe to Life Sciences